Sunmax Biotechnology Co Ltd (4728) - Total Assets
Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) holds total assets worth NT$1.90 Billion TWD (≈ $59.82 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Sunmax Biotechnology Co Ltd for net asset value and shareholders' equity analysis.
Sunmax Biotechnology Co Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data.
Sunmax Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sunmax Biotechnology Co Ltd's total assets of NT$1.90 Billion consist of 32.1% current assets and 67.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 13.1% |
| Accounts Receivable | NT$100.22 Million | 5.4% |
| Inventory | NT$125.95 Million | 6.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$5.75 Million | 0.3% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sunmax Biotechnology Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunmax Biotechnology Co Ltd's current assets represent 32.1% of total assets in 2024, a decrease from 80.1% in 2015.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, down from 71.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 6.8% of total assets.
Sunmax Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Sunmax Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sunmax Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.85 | 3.40 | 3.28 |
| Quick Ratio | 3.20 | 2.83 | 3.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$689.03 Million | NT$600.84 Million | NT$671.01 Million |
Sunmax Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sunmax Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.69 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -14.3% |
| Total Assets | NT$1.85 Billion |
| Market Capitalization | $664.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sunmax Biotechnology Co Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sunmax Biotechnology Co Ltd's assets decreased by 14.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual total assets of Sunmax Biotechnology Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.85 Billion ≈ $58.31 Million |
-14.28% |
| 2023-12-31 | NT$2.16 Billion ≈ $68.02 Million |
+20.40% |
| 2022-12-31 | NT$1.79 Billion ≈ $56.50 Million |
+20.84% |
| 2021-12-31 | NT$1.48 Billion ≈ $46.75 Million |
+8.79% |
| 2020-12-31 | NT$1.36 Billion ≈ $42.98 Million |
+22.60% |
| 2019-12-31 | NT$1.11 Billion ≈ $35.05 Million |
+46.81% |
| 2018-12-31 | NT$757.89 Million ≈ $23.88 Million |
+14.67% |
| 2017-12-31 | NT$660.92 Million ≈ $20.82 Million |
+10.62% |
| 2016-12-31 | NT$597.49 Million ≈ $18.82 Million |
-0.84% |
| 2015-12-31 | NT$602.57 Million ≈ $18.98 Million |
-- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.